{
  "meta": {
    "title": "39_Chronic_Myeloid_Leukemia",
    "url": "https://brainandscalpel.vercel.app/39-chronic-myeloid-leukemia-aba928d0.html",
    "scrapedAt": "2025-11-30T17:52:18.457Z"
  },
  "questions": [
    {
      "text": "Which of the following is correct about the Philadelphia chromosome?",
      "choices": [
        {
          "id": 0,
          "text": "Balanced translocation between long arms of chromosome 9 and 22"
        },
        {
          "id": 1,
          "text": "Balanced translocation between short arms of chromosome 9 and 22"
        },
        {
          "id": 2,
          "text": "Unbalanced translocation between long arms of chromosome 9 and 22"
        },
        {
          "id": 3,
          "text": "Unbalanced translocation between short arms of chromosome 9 and 22"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer is a: Balanced <span class=\"customMeta\" data-dictid=\"8ba7332e86169277720060bd4507c8\">translocation</span> between long arms of <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 9 and 22</strong></p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Which of the following is correct about CML?",
      "choices": [
        {
          "id": 0,
          "text": "Reciprocal exchange between breakpoint Cluster Region gene on chromosome 22, ABL1 gene on chromosome 9"
        },
        {
          "id": 1,
          "text": "Reciprocal exchange between breakpoint Cluster Region gene on chromosome 9, ABL1 gene on chromosome 22"
        },
        {
          "id": 2,
          "text": "Non-reciprocal exchange between breakpoint Cluster Region gene on chromosome 22, ABL1 gene on chromosome 9"
        },
        {
          "id": 3,
          "text": "Non-reciprocal exchange between breakpoint Cluster Region gene on chromosome 9, ABL1 gene on chromosome 22"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer is a: <span class=\"customMeta\" data-dictid=\"5afb1c86751692777197cf9452d41b\">Reciprocal</span> exchange between breakpoint Cluster Region gene on <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 22, ABL1 gene on <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 9</strong></p>\n\n<ul>\n\t<li>A part of <strong>chromosome 9</strong> at band <strong>q34</strong> (where the <strong>ABL1</strong> <span class=\"customMeta\" data-dictid=\"07aa4138b11692777196389334280a\">proto-oncogene</span> is located) breaks off.</li>\n\t<li>A part of <strong>chromosome 22</strong> at band <strong>q11</strong> (where the <strong>BCR</strong> gene is located) breaks off.</li>\n\t<li>These segments <strong>swap places</strong> (reciprocal exchange).</li>\n\t<li>The result on <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 22 is the <strong>BCR-ABL1 <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> gene</strong>, producing a constitutively active <strong>tyrosine kinase</strong>.</li>\n\t<li>This altered <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 22 is called the <strong>Philadelphia chromosome</strong>.</li>\n</ul>\n\n<p>Hack to remember: Amitabh Bachan favourite number is 9 (ABL1: <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> 9)</p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Best for management of gatekeeper mutation T315I that prevents binding and causes resistance to known TKI in Chronic myeloid leukemia is?",
      "choices": [
        {
          "id": 0,
          "text": "Dasatinib"
        },
        {
          "id": 1,
          "text": "Nilotinib"
        },
        {
          "id": 2,
          "text": "Bosutinib"
        },
        {
          "id": 3,
          "text": "Ponatinib"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Correct answer is d: Ponatinib</strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:593px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>AGENT</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>APPROVED INDICATIONS</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Imatinib mesylate</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Dasatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Nilotinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases except <span class=\"customMeta\" data-dictid=\"42eb51d31e1692777183d170489ba8\">blastic</span> phase</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Bosutinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Ponatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Optimal TKI if T315l mutation</p>\n\n\t\t\t<p>Failure of ≥2 tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitors</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Omacetaxine</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Failure ≥2 tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitors</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Bcr-abl1 fusion gene is seen in which of the following blood cancers?",
      "choices": [
        {
          "id": 0,
          "text": "ALL"
        },
        {
          "id": 1,
          "text": "AML"
        },
        {
          "id": 2,
          "text": "CLL"
        },
        {
          "id": 3,
          "text": "Hairy cell leukemia"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer is a: ALL</strong></p>\n\n<ul>\n\t<li><strong>Ph-like ALL, </strong>also known as BCR-ABL1-like ALL, is characterized by genetic lesions similar to Ph+ ALL, associated with IKZF1 (Ikaros) gene deletion</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Which of the following findings is not seen in patients with CML?",
      "choices": [
        {
          "id": 0,
          "text": "Basophilia"
        },
        {
          "id": 1,
          "text": "Low serum Vitamin B12 levels"
        },
        {
          "id": 2,
          "text": "Low NAP score"
        },
        {
          "id": 3,
          "text": "Reticulin fibrosis in bone marrow"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer is b: Low <span class=\"customMeta\" data-dictid=\"1ffaec13de169277719828374cfda0\">serum</span> vitamin B12 levels</strong></p>\n\n<ul>\n\t<li>Basophilia<strong> </strong>is seen in CML as it is a <span class=\"customMeta\" data-dictid=\"8dd789d7d1169277719303d4744837\">myeloproliferative</span> disorder.</li>\n\t<li>In CML, <span class=\"customMeta\" data-dictid=\"1ffaec13de169277719828374cfda0\">serum</span> B12 is high, not low, because increased granulocytes produce more <span class=\"customMeta\" data-dictid=\"021658ea9316927772002ed6c2a2f4\">transcobalamin</span> I, which binds B12 and is responsible for DNA synthesis</li>\n\t<li>Neutrophil Alkaline Phosphatase score<strong> </strong>is low in CML and it helps to <span class=\"customMeta\" data-dictid=\"c9001edbf216927771860f3475b44c\">differentiate</span> from <span class=\"customMeta\" data-dictid=\"340e5cd49c16927771917ee55b9e76\">leukemoid</span> reaction, where it is high. Low NAP score implies that post expiry date neutrophils that lost the ability to fight are circulating in blood stream. This explains the development of <span class=\"customMeta\" data-dictid=\"c64e3a661b1692777197afc2ff7bca\">recurrent</span> infections.</li>\n\t<li>Normal <span class=\"customMeta\" data-dictid=\"5b9831f3aa169277718395d7361df6\">bone marrow</span> has a delicate network of <span class=\"customMeta\" data-dictid=\"059559ce5d16927771975852f6a8ed\">reticulin</span> fibers that support <span class=\"customMeta\" data-dictid=\"d2e0ab499c169277718886ab5a46bf\">hematopoietic</span> cells.In CML, as the disease progresses (especially toward accelerated phase or blast crisis), there is <span class=\"customMeta\" data-dictid=\"3095c5f0fc1692777202eda8060779\">fibroblast</span> <span class=\"customMeta\" data-dictid=\"7f3792072b1692777199fd8e2c4f59\">stimulation</span> by growth factors (PDGF, TGF-β) released from <span class=\"customMeta\" data-dictid=\"458e050fdc16927771809854c9fd53\">abnormal</span> megakaryocytes and other <span class=\"customMeta\" data-dictid=\"c8a8c935a41692777191610f6aacb4\">marrow</span> cells. This leads to increased deposition of <span class=\"customMeta\" data-dictid=\"059559ce5d16927771975852f6a8ed\">reticulin</span> and “reticulin fibrosis”.</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "A 48-year-old male presents with fatigue and early satiety. On examination massive splenomegaly is seen. Work up is shown below. What is next best investigation to be done in this case\n\n\n\t\n\t\t\n\t\t\t\n\t\t\tCBC\n\t\t\t\n\t\t\t\n\t\t\tBone marrow aspiration report\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\tHb: 10.5 g/dL\n\n\t\t\tTLC: 1.5 × 10⁵ /mm³\n\n\t\t\tPlatelets: 4.0 × 10⁵ /mm³\n\t\t\t\n\t\t\t\n\t\t\tMyeloblasts: 2%, Promyelocytes: 15%, Myelocytes: 25%, Metamyelocytes: 20%\n\n\t\t\tBand forms & neutrophils: 18%, Basophils: 6%, Blasts + promyelocytes together: <10%, NAP score: low",
      "choices": [
        {
          "id": 0,
          "text": "Bone marrow biopsy"
        },
        {
          "id": 1,
          "text": "Peripheral blood FISH for BCR-ABL1"
        },
        {
          "id": 2,
          "text": "Peripheral blood RT-PCR for BCR-ABL1"
        },
        {
          "id": 3,
          "text": "G-banding cytogenetics"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer is b: <span class=\"customMeta\" data-dictid=\"255674f3271692777195c172d86daf\">Peripheral</span> blood FISH for BCR- ABL1</strong></p>\n\n<ul>\n\t<li>FISH detects the t(9;22) Philadelphia <span class=\"customMeta\" data-dictid=\"7157c1f59916927771846116d74646\">chromosome</span> or BCR-ABL1 <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> gene without cell culture, so results are quicker than G-banding. It can be done directly from <span class=\"customMeta\" data-dictid=\"255674f3271692777195c172d86daf\">peripheral</span> blood, so you avoid an <span class=\"customMeta\" data-dictid=\"1c5272ad3d1692777190e71409d07a\">invasive</span> <span class=\"customMeta\" data-dictid=\"5b9831f3aa169277718395d7361df6\">bone marrow</span> procedure.</li>\n</ul>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "A 35-year-old male with CML in chronic phase is started on imatinib. At diagnosis, bone marrow cytogenetics showed t(9;22)(q34;q11) in all metaphases. The treating physician now wants to assess whether he has achieved deep molecular remission. Which is the most appropriate investigation at this stage?",
      "choices": [
        {
          "id": 0,
          "text": "Conventional karyotyping from bone marrow aspirate"
        },
        {
          "id": 1,
          "text": "FISH for BCR-ABL on peripheral blood"
        },
        {
          "id": 2,
          "text": "Quantitative RT-PCR for BCR-ABL transcript levels"
        },
        {
          "id": 3,
          "text": "Qualitative PCR for BCR-ABL transcript"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer is c: Quantitative RT-PCR for BCR -ABL <span class=\"customMeta\" data-dictid=\"f2661b736316927772001b58b96060\">transcript</span> levels </strong></p>\n\n<p><strong>Monitoring sequence in CML</strong></p>\n\n<ol>\n\t<li><strong>Hematologic response</strong>: CBC & <span class=\"customMeta\" data-dictid=\"255674f3271692777195c172d86daf\">peripheral</span> <span class=\"customMeta\" data-dictid=\"6777533153169277719804fcbbf2d1\">smear</span> (first 3 months)</li>\n\t<li><strong>Cytogenetic response</strong>: Bone <span class=\"customMeta\" data-dictid=\"c8a8c935a41692777191610f6aacb4\">marrow</span> <span class=\"customMeta\" data-dictid=\"856149f6931692777190f9c81409c5\">karyotyping</span> / FISH (at 6–12 months)</li>\n\t<li><strong>Molecular response</strong>: Quantitative RT-PCR (qPCR) for BCR-ABL mRNA every 3–6 months thereafter</li>\n</ol>\n\n<ul>\n\t<li><strong>Deep molecular <span class=\"customMeta\" data-dictid=\"b4a3b8da7716927771975375dadad9\">remission</span> </strong>is defined as BCR-ABL ≤ 0.01% on the <em>International Scale. </em><strong>qPCR</strong> is ~100–1000× more sensitive, detecting 1 leukemic cell among 10⁵–10⁶ normal cells.</li>\n\t<li><strong>Karyotyping</strong> and <strong>FISH</strong> detect <span class=\"customMeta\" data-dictid=\"2878159c181692777185d495ce6244\">cytogenetic</span> <span class=\"customMeta\" data-dictid=\"b4a3b8da7716927771975375dadad9\">remission</span> but are less sensitive (~1–5% <span class=\"customMeta\" data-dictid=\"458e050fdc16927771809854c9fd53\">abnormal</span> cells <span class=\"customMeta\" data-dictid=\"723fdec66b1692777186e92f0c6fdf\">detection</span> limit).</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Which of the following is the most common presenting feature of CML?",
      "choices": [
        {
          "id": 0,
          "text": "Lymphadenopathy"
        },
        {
          "id": 1,
          "text": "Splenomegaly"
        },
        {
          "id": 2,
          "text": "Petechiae"
        },
        {
          "id": 3,
          "text": "Bone pain"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer is b: Splenomegaly </strong></p>\n\n<ul>\n\t<li>CML often presents insidiously with symptoms related to splenic <span class=\"customMeta\" data-dictid=\"41e56d9a54169277718724ff8c225f\">enlargement</span> (fullness, early satiety, LUQ pain) and <span class=\"customMeta\" data-dictid=\"fa22689e5916927771893dbf179f21\">hypermetabolism</span> (fever, weight loss, night sweats).</li>\n</ul>\n\n<p> </p>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "Which of the following drugs is approved for CML in case of failure of >2 or more TKI",
      "choices": [
        {
          "id": 0,
          "text": "Omacetaxine"
        },
        {
          "id": 1,
          "text": "Dasatinib"
        },
        {
          "id": 2,
          "text": "Bosutinib"
        },
        {
          "id": 3,
          "text": "Nilotinib"
        }
      ],
      "correct_choice_id": 0,
      "solution": "<p><strong>Correct answer is a: Omacetaxine </strong></p>\n\n<table cellspacing=\"0\" style=\"border-collapse:collapse; width:593px\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>AGENT</strong></p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p><strong>APPROVED INDICATIONS</strong></p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Imatinib mesylate</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Dasatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Nilotinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases except <span class=\"customMeta\" data-dictid=\"42eb51d31e1692777183d170489ba8\">blastic</span> phase</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Bosutinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>All phases</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Ponatinib</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Optimal TKI if T315l mutation</p>\n\n\t\t\t<p>Failure of ≥2 tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitors</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Omacetaxine</p>\n\t\t\t</td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n\t\t\t<p>Failure ≥2 tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitors</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "48-year-old man presents with fatigue, headache, and visual blurring. Examination reveals splenomegaly. CBC shows: Hb 9.8 g/dL, TLC 1.2 × 10⁵/µL, platelet count 650 × 10³/µL. Peripheral smear shows marked myeloid proliferation with occasional myeloblasts. Fundoscopy reveals retinal vein engorgement. Which of the following is the most appropriate immediate next step in management?",
      "choices": [
        {
          "id": 0,
          "text": "Start imatinib therapy"
        },
        {
          "id": 1,
          "text": "Leukapheresis"
        },
        {
          "id": 2,
          "text": "Hydroxyurea + hydration"
        },
        {
          "id": 3,
          "text": "Allopurinol prophylaxis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Correct answer is b: Leukapheresis </strong></p>\n\n<ul>\n\t<li>This patient with CML has <span class=\"customMeta\" data-dictid=\"509310d4411692777199f2ffdb7769\">symptomatic</span> <span class=\"customMeta\" data-dictid=\"5bb53e53c21692777189c97c52d6ae\">hyperleukocytosis</span> (headache, visual symptoms, <span class=\"customMeta\" data-dictid=\"fb7a2c30e416927771972f7df6f8c0\">retinal</span> <span class=\"customMeta\" data-dictid=\"75ddd4cc7016927772012e0acd424d\">vein</span> engorgement).</li>\n\t<li><strong>Leukostasis</strong> is a medical emergency; immediate <span class=\"customMeta\" data-dictid=\"14211de5fa16927771858ffe217771\">cytoreduction</span> is needed. Leukapheresis rapidly lowers WBC count and relieves symptoms, while <span class=\"customMeta\" data-dictid=\"ac923489f3169277718998b7f862df\">hydroxyurea</span> can be added for ongoing control.</li>\n\t<li><strong>Imatinib</strong> is for <span class=\"customMeta\" data-dictid=\"32b854324a1692777185c6c79fdc99\">definitive</span> therapy but should be started after stabilization.</li>\n\t<li>Allopurinol is for <strong>tumor <span class=\"customMeta\" data-dictid=\"803b5ed1c8169277719190b446ac83\">lysis</span> prevention</strong>, not <span class=\"customMeta\" data-dictid=\"4cdc8161f71692777180df58cafa93\">acute</span> management of leukostasis.</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    },
    {
      "text": "70-year-old male presents with fatigue, unintentional weight loss, and recurrent respiratory infections over the last 6 months. Examination reveals pallor and mild splenomegaly.\n\nCBC shows:\n\n\n\tHb: 9.8 g/dL\n\tTLC: 28,000/µL (Monocytes: 5,500/µL)\n\tPlatelets: 110,000/µL\n\n\nPeripheral smear shows monocytosis with occasional myelocytes and metamyelocytes. Bone marrow aspirate is hypercellular with increased monocytes, <20% blasts, and dysplastic features in granulocytic and megakaryocytic lineages.\n\nCytogenetic analysis is negative for the Philadelphia chromosome\n\nDiagnosis is?",
      "choices": [
        {
          "id": 0,
          "text": "CML"
        },
        {
          "id": 1,
          "text": "AML"
        },
        {
          "id": 2,
          "text": "CMML"
        },
        {
          "id": 3,
          "text": "JMML"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Correct answer is c: CMML</strong></p>\n\n<ul>\n\t<li>CMML (chronic <span class=\"customMeta\" data-dictid=\"215dafdbad1692777193dcb48ddd63\">myelomonocytic</span> leukemia) is a myelodysplastic/myeloproliferative <span class=\"customMeta\" data-dictid=\"1622f69a94169277719372b76236ca\">neoplasm</span> characterized by persistent <span class=\"customMeta\" data-dictid=\"cc8beb11041692777192b19dfb290a\">monocytosis</span> (>1 × 10⁹/L) and <span class=\"customMeta\" data-dictid=\"984733db481692777186757cce6e6b\">dysplasia</span> in ≥1 <span class=\"customMeta\" data-dictid=\"da88d7f2211692777193037caba514\">myeloid</span> line.</li>\n\t<li>To diagnose CMML, <strong>CML must be excluded</strong> by ruling out <strong>BCR-ABL1</strong> <span class=\"customMeta\" data-dictid=\"a7dfeb385e1692777203302bcf142d\">fusion</span> (via PCR or FISH).</li>\n\t<li>Juvenile Chronic <span class=\"customMeta\" data-dictid=\"215dafdbad1692777193dcb48ddd63\">myelomonocytic</span> <span class=\"customMeta\" data-dictid=\"4521dbf4b91692777191a73002bf98\">leukemia</span> is ruled out based on age and absence of elevated Hb F.</li>\n</ul>\n\n<p> </p>",
      "question_images": [],
      "explanation_video": null,
      "explanation_images": [],
      "explanation_audio_eng": null,
      "explanation_audio_hin": null
    }
  ]
}